Objectif BBH Biotech Polska was created with a thought of using sound waves to enhance and control microbial metabolism. After 3 years of research the team created a company and focused on using sound waves as a stimulating factor in enhancing alcohol production. From the day the company was established, its strategy and long term aim was to adjust its technology of sonic fermentation enhancement to recombinant proteins, fine chemicals and drug production.The biggest problem in recombinant protein production using microbial expression systems is that a part of produced proteins are being stuck in the periplasmic space while being transported outside the cell. Treating such loaded microorganisms with adjusted sound waves can destabilize the inner membrane and outer wall in order to reclaim those proteins. This innovative procedure allows the molecules to escape the periplasmic space to the cultivation medium without destroying the cell, which was so far the biggest obstacle.Currently there are only few available methods that solve this problem, and BBH Biotech Polska is the only company developing such solution in a form of technology which is highly effective and after Phase 1 – ready to enter the market.Users of this technology will be companies producing human and animal pharmaceutical proteins with microbial expression systems. Such pharmaceuticals are expensive products, which means that an increase in production even by little, e.g. 3 – 7%, is enough to give that company an annual increase in revenue form 30 even up to 80 million dollarsOur technology increases production yield from a single cultivation from 30% to 90%, depending on the protein and the expression system. Such boost to productivity will not only hasten the growth of the market, but also decrease the cost of producing e.g. insulin or platelet factors. The corresponding drugs that use them as an active compound for diabetics or patients suffering from blood clotting disorders will also cheapen. Champ scientifique natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsnatural sciencesbiological sciencesmicrobiologymedical and health sciencesbasic medicinepharmacology and pharmacysocial scienceseconomics and businessbusiness and managementcommerce Programme(s) H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Thème(s) SMEInst-03-2016-2017 - Dedicated support to biotechnology SMEs closing the gap from lab to market Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur BBH BIOTECH POLSKA SPOLKA Z OGRANICZONA OPDOWIEDZIALNOSCIA Contribution nette de l'UE € 50 000,00 Adresse UL. RUBIEZ 46H/250 61 612 POZNAN Pologne Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Makroregion północno-zachodni Wielkopolskie Miasto Poznań Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
